OncRef

Clinical Trial: NCT06360575

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-10-19

Study Overview

Brief Summary

This phase II MATCH treatment trial tests how well crizotinib works to treat patients with cancers with MET exon 14 deletion genetic changes. Crizotinib is in a group of medications called tyrosine kinase inhibitors. It works by blocking enzymes that cancer cells need to grow and spread. It may also prevent the growth of new blood vessels that tumors need to grow.

Official Title

MATCH Treatment Subprotocol C2: Crizotinib in Patients With Tumors With MET Exon 14 Deletion

Conditions

Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma

Intervention / Treatment

  • Procedure: Biopsy Procedure
  • Procedure: Biospecimen Collection
  • Drug: Crizotinib
  • Procedure: Radiologic Examination

Other Study ID Numbers

  • NCI-2024-01127
  • NCI-2024-01127
  • EAY131-C2
  • EAY131-C2
  • U10CA180820

Start Date (Actual)

2016-07-20

Primary Completion Date (Actual)

2022-11-15

Study Completion Date (Estimated)

2026-12-31

Enrollment (Actual)

20

Study Type

Interventional

Phase

Phase 2